Imperial College London is running a clinical study called BEAD-PC that places a blood test for Alzheimer's disease directly into North West London GP appointments. The test, PrecivityAD2 by C2N Diagnostics, detects amyloid plaques in the brain and is designed for adults aged 50 and older showing early signs of cognitive decline. Patients with concerning results are fast-tracked to Imperial's specialist Memory Unit. The study is part of a global Davos Alzheimer's Collaborative program, with Imperial as the sole UK site. The goal is to build evidence that blood-based biomarker testing can work at scale within the NHS, potentially replacing slower and costlier diagnostic pathways and getting patients into treatment sooner.
